Ramipril is cost effective treatment for cardiovascular risk reduction in patients at medium, high and low pre-treatment risk. We suppose 300-700 thousand of patients to live in Hungary whose state of health would improve by taking ramipril. In the case of ramipril therapy, the estimated cost of one life year gained is 2.1-6.3 million HUF, depending on the specific age group (different risk portfolio). By the proper application of the therapy, probably, 2,0002,700 lives could be saved annually, and a five-year-long ramipril therapy would yield the save of approximately 30,000-50,000 life years.
|Translated title of the contribution||Drug therapy of high risk cardiovascular patients: Evidence Based Medicine|
|Number of pages||11|
|Publication status||Published - Dec 1 2002|
ASJC Scopus subject areas